VanEck Associates’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $301M | Sell |
3,501,654
-262,266
| -7% | -$23M | 0.18% | 80 |
|
|
2026
Q1 | $340M | Buy |
3,763,920
+150,495
| +4% | +$13.8M | 0.26% | 73 |
|
|
2025
Q4 | $325M | Buy |
3,613,425
+136,519
| +4% | +$12.9M | 0.27% | 80 |
|
|
2025
Q3 | $342M | Buy |
3,476,906
+82,375
| +2% | +$8.16M | 0.32% | 71 |
|
|
2025
Q2 | $310M | Sell |
3,394,531
-257,860
| -7% | -$24.9M | 0.35% | 65 |
|
|
2025
Q1 | $413M | Sell |
3,652,391
-303,058
| -8% | -$32.4M | 0.53% | 43 |
|
|
2024
Q4 | $418M | Buy |
3,955,449
+218,688
| +6% | +$23.5M | 0.53% | 48 |
|
|
2024
Q3 | $391M | Buy |
3,736,761
+411,163
| +12% | +$44.9M | 0.49% | 57 |
|
|
2024
Q2 | $361M | Buy |
3,325,598
+167,038
| +5% | +$19.7M | 0.51% | 54 |
|
|
2024
Q1 | $417M | Buy |
3,158,560
+320,002
| +11% | +$40M | 0.63% | 39 |
|
|
2023
Q4 | $345M | Buy |
2,838,558
+543,344
| +24% | +$60.6M | 0.63% | 55 |
|
|
2023
Q3 | $258M | Buy |
2,295,214
+359,506
| +19% | +$45.7M | 0.57% | 59 |
|
|
2023
Q2 | $282M | Buy |
1,935,708
+344,858
| +22% | +$46.9M | 0.62% | 38 |
|
|
2023
Q1 | $206M | Buy |
1,590,850
+138,623
| +10% | +$17.4M | 0.47% | 60 |
|
|
2022
Q4 | $185M | Sell |
1,452,227
-107,153
| -7% | -$12.4M | 0.48% | 50 |
|
|
2022
Q3 | $163M | Buy |
1,559,380
+67,448
| +5% | +$7.4M | 0.49% | 54 |
|
|
2022
Q2 | $157M | Buy |
1,491,932
+12,901
| +0.9% | +$1.53M | 0.42% | 66 |
|
|
2022
Q1 | $189M | Buy |
1,479,031
+150,410
| +11% | +$18.1M | 0.39% | 65 |
|
|
2021
Q4 | $164M | Buy |
1,328,621
+108,756
| +9% | +$14.2M | 0.38% | 78 |
|
|
2021
Q3 | $173M | Buy |
1,219,865
+163,368
| +15% | +$24M | 0.44% | 65 |
|
|
2021
Q2 | $165M | Buy |
1,056,497
+186,088
| +21% | +$30.1M | 0.39% | 72 |
|
|
2021
Q1 | $135M | Buy |
870,409
+117,261
| +16% | +$18.2M | 0.37% | 73 |
|
|
2020
Q4 | $113M | Buy |
753,148
+50,512
| +7% | +$7.13M | 0.33% | 73 |
|
|
2020
Q3 | $92.9M | Sell |
702,636
-64,719
| -8% | -$8.45M | 0.3% | 64 |
|
|
2020
Q2 | $88.9M | Buy |
767,355
+131,068
| +21% | +$15.1M | 0.31% | 64 |
|
|
2020
Q1 | $62.4M | Buy |
636,287
+43,469
| +7% | +$5.7M | 0.32% | 74 |
|
|
2019
Q4 | $86.1M | Buy |
592,818
+70,476
| +13% | +$9.73M | 0.33% | 72 |
|
|
2019
Q3 | $69.6M | Buy |
522,342
+38,179
| +8% | +$4.93M | 0.33% | 63 |
|
|
2019
Q2 | $55.3M | Buy |
484,163
+15,277
| +3% | +$1.79M | 0.27% | 90 |
|
|
2019
Q1 | $58.1M | Buy |
468,886
+86,725
| +23% | +$9.86M | 0.29% | 79 |
|
|
2018
Q4 | $38.5M | Buy |
382,161
+46,182
| +14% | +$5.19M | 0.19% | 108 |
|
|
2018
Q3 | $42.9M | Buy |
335,979
+10,035
| +3% | +$1.19M | 0.21% | 111 |
|
|
2018
Q2 | $35.3M | Buy |
325,944
+30,391
| +10% | +$3.31M | 0.16% | 133 |
|
|
2018
Q1 | $31.3M | Buy |
295,553
+7,155
| +2% | +$831K | 0.16% | 135 |
|
|
2017
Q4 | $33.8M | Buy |
288,398
+15,863
| +6% | +$1.79M | 0.17% | 129 |
|
|
2017
Q3 | $31M | Buy |
272,535
+19,654
| +8% | +$2.27M | 0.16% | 142 |
|
|
2017
Q2 | $31.5M | Buy |
252,881
+13,384
| +6% | +$1.59M | 0.17% | 107 |
|
|
2017
Q1 | $28.4M | Buy |
239,497
+132,431
| +124% | +$15M | 0.13% | 136 |
|
|
2016
Q4 | $10.7M | Buy |
+107,066
| New | +$11.5M | 0.05% | 214 |
|
Other funds holding ZBH
VanEck Associates's ZBH Position: Q2 2026 in Review
VanEck Associates reduced its Zimmer Biomet (ZBH) stake by 7% in Q2 2026, selling an estimated $23M and leaving 3,501,654 shares worth $301M. The position accounts for 0.18% of the portfolio, ranked #80.
VanEck Associates first reported a position in ZBH in Q4 2016 and has held it in 39 quarters since. The position peaked at $418M in Q4 2024. 906 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.
- VanEck Associates held 3,501,654 shares of Zimmer Biomet worth $301M as of Q2 2026.
- VanEck Associates sold 262,266 Zimmer Biomet shares in Q2 2026, an estimated $23M.
- Zimmer Biomet made up 0.18% of VanEck Associates's portfolio in Q2 2026, its #80 holding.
- VanEck Associates first reported a position in Zimmer Biomet in Q4 2016 and has held it in 39 quarters since.
- VanEck Associates's Zimmer Biomet position peaked at $418M in Q4 2024.
- 906 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.